Compare CUE & PODC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUE | PODC |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 56.5M |
| IPO Year | 2018 | N/A |
| Metric | CUE | PODC |
|---|---|---|
| Price | $0.30 | $2.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 54.9K |
| Earning Date | 11-12-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,100,000.00 | ★ $56,957,000.00 |
| Revenue This Year | N/A | $17.27 |
| Revenue Next Year | $25.00 | $19.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.01 |
| 52 Week Low | $0.23 | $1.28 |
| 52 Week High | $1.54 | $2.94 |
| Indicator | CUE | PODC |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 55.65 |
| Support Level | $0.27 | $2.37 |
| Resistance Level | $0.37 | $2.70 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 23.35 | 68.48 |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.